Search

Your search keyword '"Van Lanschot, Jan"' showing total 417 results
Start Over Author "Van Lanschot, Jan"
417 results on '"Van Lanschot, Jan"'

1. Impact of 18FFDG-PET/CT and Laparoscopy in Staging of Locally Advanced Gastric Cancer: A Cost Analysis in the Prospective Multicenter PLASTIC-Study

Author

de Jongh, Cas, van der Meulen, Miriam P., Gertsen, Emma C., Brenkman, Hylke J. F., van Sandick, Johanna W., van Berge Henegouwen, Mark I., Gisbertz, Suzanne S., Luyer, Misha D. P., Nieuwenhuijzen, Grard A. P., van Lanschot, Jan J. B., Lagarde, Sjoerd M., Wijnhoven, Bas P. L., de Steur, Wobbe O., Hartgrink, Henk H., Stoot, Jan H. M. B., Hulsewe, Karel W. E., Spillenaar Bilgen, Ernst Jan, van Det, Marc J., Kouwenhoven, Ewout A., Daams, Freek, van der Peet, Donald L., van Grieken, Nicole C. T., Heisterkamp, Joos, van Etten, Boudewijn, van den Berg, Jan-Willem, Pierie, Jean-Pierre, Eker, Hasan H., Thijssen, Annemieke Y., Belt, Eric J. T., van Duijvendijk, Peter, Wassenaar, Eelco, Wevers, Kevin P., Hol, Lieke, Wessels, Frank J., Haj Mohammad, Nadia, Frederix, Geert W. J., van Hillegersberg, Richard, Siersema, Peter D., Vegt, Erik, and Ruurda, Jelle P.

Published
2024
Full Text
View/download PDF

3. Pain and Opioid Consumption After Laparoscopic Versus Open Gastrectomy for Gastric Cancer: A Secondary Analysis of a Multicenter Randomized Clinical Trial (LOGICA-Trial)

Author

van der Veen, Arjen, Ramaekers, Mark, Marsman, Marije, Brenkman, Hylke J.F., Seesing, Maarten F.J., Luyer, Misha D.P., Nieuwenhuijzen, Grard A.P., Stoot, Jan H.M.B., Tegels, Juul J.W., Wijnhoven, Bas P.L., de Steur, Wobbe O., Kouwenhoven, Ewout A., Wassenaar, Eelco B., Draaisma, Werner A., Gisbertz, Suzanne S., van der Peet, Donald L., May, Anne M., Ruurda, Jelle P., van Hillegersberg, Richard, Haverkamp, Leonie, Ponten, Jeroen E.H., Heesakkers, Fanny F.B.M., Hulsewe, Karel W.E., Tweed, Thais T.T., Lagarde, Sjoerd M., van Lanschot, Jan J.B., Hartgrink, Henk H., van Det, Marc J., van Duijvendijk, Peter, van der Zaag, Edwin S., Broeders, Ivo A.M.J., van Berge Henegouwen, Mark I., and Daams, Freek

Published
2023
Full Text
View/download PDF

5. Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction:A Network Meta-Analysis

Author

Ronellenfitsch, Ulrich, Friedrichs, Juliane, Barbier, Emilie, Bass, Gary A., Burmeister, Bryan, Cunningham, David, Eyck, Ben M., Grilli, Maurizio, Hofheinz, Ralf Dieter, Kieser, Meinhard, Kleeff, Jörg, Klevebro, Fredrik, Langley, Ruth, Lordick, Florian, Lutz, Manfred, Mauer, Murielle, Michalski, Christoph W., Michl, Patrick, Nankivell, Matthew, Nilsson, Magnus, Seide, Svenja, Shah, Manish A., Shi, Qian, Stahl, Michael, Urba, Susan, Van Lanschot, Jan, Vordermark, Dirk, Walsh, Thomas Noel, Ychou, Marc, Proctor, Tanja, Vey, Johannes A., Ronellenfitsch, Ulrich, Friedrichs, Juliane, Barbier, Emilie, Bass, Gary A., Burmeister, Bryan, Cunningham, David, Eyck, Ben M., Grilli, Maurizio, Hofheinz, Ralf Dieter, Kieser, Meinhard, Kleeff, Jörg, Klevebro, Fredrik, Langley, Ruth, Lordick, Florian, Lutz, Manfred, Mauer, Murielle, Michalski, Christoph W., Michl, Patrick, Nankivell, Matthew, Nilsson, Magnus, Seide, Svenja, Shah, Manish A., Shi, Qian, Stahl, Michael, Urba, Susan, Van Lanschot, Jan, Vordermark, Dirk, Walsh, Thomas Noel, Ychou, Marc, Proctor, Tanja, and Vey, Johannes A.

Abstract

Importance: The prognosis of patients with adenocarcinoma of the esophagus and esophagogastric junction (AEG) is poor. From current evidence, it remains unclear to what extent preoperative chemoradiotherapy (CRT) or preoperative and/or perioperative chemotherapy achieve better outcomes than surgery alone. Objective: To assess the association of preoperative CRT and preoperative and/or perioperative chemotherapy in patients with AEG with overall survival and other outcomes. Data Sources:Literature search in PubMed, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, ClinicalTrials.gov, and International Clinical Trials Registry Platform was performed from inception to April 21, 2023. Study Selection: Two blinded reviewers screened for randomized clinical trials comparing preoperative CRT plus surgery with preoperative and/or perioperative chemotherapy plus surgery, 1 intervention with surgery alone, or all 3 treatments. Only data from participants with AEG were included from trials that encompassed mixed histology or gastric cancer. Among 2768 initially identified studies, 17 (0.6%) met the selection criteria. Data Extraction and Synthesis: The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines were followed for extracting data and assessing data quality by 2 independent extractors. A bayesian network meta-analysis was conducted using the 2-stage approach. Main Outcomes and Measures: Overall and disease-free survival, postoperative morbidity, and mortality. Results:The analyses included 2549 patients (2206 [86.5%] male; mean [SD] age, 61.0 [9.4] years) from 17 trials (conducted from 1989-2016). Both preoperative CRT plus surgery (hazard ratio [HR], 0.75 [95% credible interval (CrI), 0.62-0.90]; 3-year difference, 105 deaths per 1000 patients) and preoperativ

Published
2024

6. Impact of 18FFDG-PET/CT and Laparoscopy in Staging of Locally Advanced Gastric Cancer:A Cost Analysis in the Prospective Multicenter PLASTIC-Study

Author

de Jongh, Cas, Gertsen, Emma C., van der Meulen, Miriam P., Brenkman, Hylke J.F., van Sandick, Johanna W., van Berge Henegouwen, Mark I., Gisbertz, Suzanne S., Luyer, Misha D.P., Nieuwenhuijzen, Grard A.P., van Lanschot, Jan J.B., Lagarde, Sjoerd M., Wijnhoven, Bas P.L., de Steur, Wobbe O., Hartgrink, Henk H., Stoot, Jan H.M.B., Hulsewe, Karel W.E., Spillenaar Bilgen, Ernst Jan, van Det, Marc J., Kouwenhoven, Ewout A., Daams, Freek, van der Peet, Donald L., van Grieken, Nicole C.T., Heisterkamp, Joos, van Etten, Boudewijn, van den Berg, Jan Willem, Pierie, Jean Pierre, Eker, Hasan H., Thijssen, Annemieke Y., Belt, Eric J.T., van Duijvendijk, Peter, Wassenaar, Eelco, Wevers, Kevin P., Hol, Lieke, Wessels, Frank J., Haj Mohammad, Nadia, Frederix, Geert W.J., van Hillegersberg, Richard, Siersema, Peter D., Vegt, Erik, Ruurda, Jelle P., de Jongh, Cas, Gertsen, Emma C., van der Meulen, Miriam P., Brenkman, Hylke J.F., van Sandick, Johanna W., van Berge Henegouwen, Mark I., Gisbertz, Suzanne S., Luyer, Misha D.P., Nieuwenhuijzen, Grard A.P., van Lanschot, Jan J.B., Lagarde, Sjoerd M., Wijnhoven, Bas P.L., de Steur, Wobbe O., Hartgrink, Henk H., Stoot, Jan H.M.B., Hulsewe, Karel W.E., Spillenaar Bilgen, Ernst Jan, van Det, Marc J., Kouwenhoven, Ewout A., Daams, Freek, van der Peet, Donald L., van Grieken, Nicole C.T., Heisterkamp, Joos, van Etten, Boudewijn, van den Berg, Jan Willem, Pierie, Jean Pierre, Eker, Hasan H., Thijssen, Annemieke Y., Belt, Eric J.T., van Duijvendijk, Peter, Wassenaar, Eelco, Wevers, Kevin P., Hol, Lieke, Wessels, Frank J., Haj Mohammad, Nadia, Frederix, Geert W.J., van Hillegersberg, Richard, Siersema, Peter D., Vegt, Erik, and Ruurda, Jelle P.

Abstract

Background: Unnecessary D2-gastrectomy and associated costs can be prevented after detecting non-curable gastric cancer, but impact of staging on treatment costs is unclear. This study determined the cost impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FFDG-PET/CT) and staging laparoscopy (SL) in gastric cancer staging. Materials and Methods:In this cost analysis, four staging strategies were modeled in a decision tree: (1) 18FFDG-PET/CT first, then SL, (2) SL only, (3) 18FFDG-PET/CT only, and (4) neither SL nor 18FFDG-PET/CT. Costs were assessed on the basis of the prospective PLASTIC-study, which evaluated adding 18FFDG-PET/CT and SL to staging advanced gastric cancer (cT3–4 and/or cN+) in 18 Dutch hospitals. The Dutch Healthcare Authority provided 18FFDG-PET/CT unit costs. SL unit costs were calculated bottom-up. Gastrectomy-associated costs were collected with hospital claim data until 30 days postoperatively. Uncertainty was assessed in a probabilistic sensitivity analysis (1000 iterations). Results: 18FFDG-PET/CT costs were €1104 including biopsy/cytology. Bottom-up calculations totaled €1537 per SL. D2-gastrectomy costs were €19,308. Total costs per patient were €18,137 for strategy 1, €17,079 for strategy 2, and €19,805 for strategy 3. If all patients undergo gastrectomy, total costs were €18,959 per patient (strategy 4). Performing SL only reduced costs by €1880 per patient. Adding 18FFDG-PET/CT to SL increased costs by €1058 per patient; IQR €870–1253 in the sensitivity analysis. Conclusions:For advanced gastric cancer, performing SL resulted in substantial cost savings by reducing unnecessary gastrectomies. In contrast, routine 18FFDG-PET/CT increased costs without substantially reducing unnecessary gastrectomies, and is not recomme

Published
2024

7. Development of a Reliable Surgical Quality Assurance System for 2-stage Esophagectomy in Randomized Controlled Trials

Author

Harris, Alexander, Butterworth, James, Boshier, Piers R., MacKenzie, Hugh, Tokunaga, Masanori, Sunagawa, Hideki, Mavroveli, Stella, Ni, Melody, Mikhail, Sameh, Yeh, Chi-Chuan, Blencowe, Natalie S., Avery, Kerry N. L., Hardwick, Richard, Hoelscher, Arnulf, Pera, Manuel, Zaninotto, Giovanni, Law, Simon, Low, Donald E., van Lanschot, Jan J. B., Berrisford, Richard, Barham, Christopher Paul, Blazeby, Jane M., and Hanna, George B.

Published
2022
Full Text
View/download PDF

8. Chemotherapy and chemoradiotherapy for adenocarcinoma of the esophagus and junction with oligometastases: Results of the TNT-OES-1 trial.

Author

van der Zijden, Charlène J., primary, Huizer, Tamara J., additional, Eyck, Ben M., additional, van der Gaast, Ate, additional, Van Doorn, Leni, additional, Homs, Marjolein Y.V., additional, van Lanschot, Jan J.B., additional, Nuyttens, Joost J.M.E., additional, Oudijk, Lindsey, additional, Spaander, Manon C.W., additional, Wijnhoven, Bas P.L., additional, Mostert, Bianca, additional, and Lagarde, Sjoerd M., additional

Published
2024
Full Text
View/download PDF

9. Impact of 18FFDG-PET/CT and Laparoscopy in Staging of Locally Advanced Gastric Cancer: A Cost Analysis in the Prospective Multicenter PLASTIC-Study.

Author

de Jongh, Cas, van der Meulen, Miriam P., Gertsen, Emma C., Brenkman, Hylke J. F., van Sandick, Johanna W., van Berge Henegouwen, Mark I., Gisbertz, Suzanne S., Luyer, Misha D. P., Nieuwenhuijzen, Grard A. P., van Lanschot, Jan J. B., Lagarde, Sjoerd M., Wijnhoven, Bas P. L., de Steur, Wobbe O., Hartgrink, Henk H., Stoot, Jan H. M. B., Hulsewe, Karel W. E., Spillenaar Bilgen, Ernst Jan, van Det, Marc J., Kouwenhoven, Ewout A., and Daams, Freek

Abstract

Background: Unnecessary D2-gastrectomy and associated costs can be prevented after detecting non-curable gastric cancer, but impact of staging on treatment costs is unclear. This study determined the cost impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FFDG-PET/CT) and staging laparoscopy (SL) in gastric cancer staging. Materials and Methods: In this cost analysis, four staging strategies were modeled in a decision tree: (1) 18FFDG-PET/CT first, then SL, (2) SL only, (3) 18FFDG-PET/CT only, and (4) neither SL nor 18FFDG-PET/CT. Costs were assessed on the basis of the prospective PLASTIC-study, which evaluated adding 18FFDG-PET/CT and SL to staging advanced gastric cancer (cT3–4 and/or cN+) in 18 Dutch hospitals. The Dutch Healthcare Authority provided 18FFDG-PET/CT unit costs. SL unit costs were calculated bottom-up. Gastrectomy-associated costs were collected with hospital claim data until 30 days postoperatively. Uncertainty was assessed in a probabilistic sensitivity analysis (1000 iterations). Results: 18FFDG-PET/CT costs were €1104 including biopsy/cytology. Bottom-up calculations totaled €1537 per SL. D2-gastrectomy costs were €19,308. Total costs per patient were €18,137 for strategy 1, €17,079 for strategy 2, and €19,805 for strategy 3. If all patients undergo gastrectomy, total costs were €18,959 per patient (strategy 4). Performing SL only reduced costs by €1880 per patient. Adding 18FFDG-PET/CT to SL increased costs by €1058 per patient; IQR €870–1253 in the sensitivity analysis. Conclusions: For advanced gastric cancer, performing SL resulted in substantial cost savings by reducing unnecessary gastrectomies. In contrast, routine 18FFDG-PET/CT increased costs without substantially reducing unnecessary gastrectomies, and is not recommended due to limited impact with major costs. Trial registration: NCT03208621. This trial was registered prospectively on 30-06-2017. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Lasting Symptoms After Esophageal Resection (LASER): European Multicenter Cross-sectional Study

Author

Markar, Sheraz R., Zaninotto, Giovanni, Castoro, Carlo, Johar, Asif, Lagergren, Pernilla, Elliott, Jessie A., Gisbertz, Suzanne S., Mariette, Christophe, Alfieri, Rita, Huddy, Jeremy, Sounderajah, Viknesh, Pinto, Eleonora, Scarpa, Marco, Klevebro, Fredrik, Sunde, Berit, Murphy, Conor F., Greene, Christine, Ravi, Narayanasamy, Piessen, Guillaume, Brenkman, Hylke, Ruurda, Jelle P., Van Hillegersberg, Richard, Lagarde, Sjoerd, Wijnhoven, Bas, Pera, Manuel, Roig, José, Castro, Sandra, Matthijsen, Robert, Findlay, John, Antonowicz, Stefan, Maynard, Nick, McCormack, Orla, Ariyarathenam, Arun, Sanders, Grant, Cheong, Edward, Jaunoo, Shameen, Allum, William, Van Lanschot, Jan, Nilsson, Magnus, Reynolds, John V., van Berge Henegouwen, Mark I., and Hanna, George B.

Published
2020
Full Text
View/download PDF

14. Esophageal cancer patients’ need for information and support in making a treatment decision between standard surgery and active surveillance

Author

Hermus, Merel, primary, van der Wilk, Berend J., additional, Chang, Rebecca, additional, Dekker, Jan Willem T., additional, Coene, Peter‐Paul L. O., additional, Nieuwenhuijzen, Grard A. P., additional, Rosman, Camiel, additional, Heisterkamp, Joos, additional, Hartgrink, Henk H., additional, Timmermans, Liesbeth, additional, Wijnhoven, Bas P. L., additional, van der Zijden, Charlène J., additional, van Lanschot, Jan J. B., additional, Busschbach, Jan, additional, Lagarde, Sjoerd M., additional, and Kranenburg, Leonieke W., additional

Published
2023
Full Text
View/download PDF

15. Surgeon's steering behaviour towards patients to participate in a cluster randomised trial on active surveillance for oesophageal cancer: A qualitative study

Author

de Veer, Mathijs R., primary, Hermus, Merel, additional, van der Zijden, Charlène J., additional, van der Wilk, Berend J., additional, Wijnhoven, Bas P.L., additional, Stiggelbout, Anne M., additional, Dekker, Jan Willem T., additional, Coene, Peter Paul L.O., additional, Busschbach, Jan J., additional, van Lanschot, Jan J.B., additional, Lagarde, Sjoerd M., additional, and Kranenburg, Leonieke W., additional

Published
2023
Full Text
View/download PDF

16. Risk Prediction Model of 90-Day Mortality after Esophagectomy for Cancer

Author

D'Journo, Xavier Benoit, Boulate, David, Fourdrain, Alex, Loundou, Anderson, van Berge Henegouwen, Mark I, Gisbertz, Suzanne S, O'Neill, J Robert, Hoelscher, Arnulf, Piessen, Guillaume, van Lanschot, Jan, Wijnhoven, Bas, Jobe, Blair, Davies, Andrew, Schneider, Paul M, Pera, Manuel, Nilsson, Magnus, Nafteux, Philippe, Kitagawa, Yuko, Morse, Christopher R, Hofstetter, Wayne, Molena, Daniela, Jimmy Bok-Yan, So, Immanuel, Arul, Parsons, Simon L, Larsen, Michael Hareskov, Dolan, James P, Wood, Stephanie G, Maynard, Nick, Smithers, Mark, Puig, Sonia, Law, Simon, Wong, Ian, Kennedy, Andrew, Kangning, Wang, Reynolds, John V, Pramesh, C S, Ferguson, Mark, Darling, Gail, Schröder, Wolfgang, Bludau, Marc, Underwood, Tim, van Hillegersberg, Richard, Chang, Andrew, Cecconello, Ivan, Ribeiro, Ulysses, de Manzoni, Giovanni, Rosati, Riccardo, Kuppusamy, Madhankumar, Thomas, Pascal Alexandre, Low, Donald E, Weindelmayer, J., Surgery, CCA - Cancer Treatment and Quality of Life, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, D'Journo, Xavier Benoit, Boulate, David, Fourdrain, Alex, Loundou, Anderson, van Berge Henegouwen, Mark I, Gisbertz, Suzanne S, O'Neill, J Robert, Hoelscher, Arnulf, Piessen, Guillaume, van Lanschot, Jan, Wijnhoven, Ba, Jobe, Blair, Davies, Andrew, Schneider, Paul M, Pera, Manuel, Nilsson, Magnu, Nafteux, Philippe, Kitagawa, Yuko, Morse, Christopher R, Hofstetter, Wayne, Molena, Daniela, So, Jimmy Bok-Yan, Immanuel, Arul, Parsons, Simon L, Larsen, Michael Hareskov, Dolan, James P, Wood, Stephanie G, Maynard, Nick, Smithers, Mark, Puig, Sonia, Law, Simon, Wong, Ian, Kennedy, Andrew, Kangning, Wang, Reynolds, John V, Pramesh, C S, Ferguson, Mark, Darling, Gail, Schröder, Wolfgang, Bludau, Marc, Underwood, Tim, van Hillegersberg, Richard, Chang, Andrew, Cecconello, Ivan, Ribeiro, Ulysse, de Manzoni, Giovanni, Rosati, Riccardo, Kuppusamy, Madhankumar, Thomas, Pascal Alexandre, and Low, Donald E

Subjects
Male, medicine.medical_specialty, Time Factors, Esophageal Neoplasms, medicine.medical_treatment, 030230 surgery, Logistic regression, Risk Assessment, 03 medical and health sciences, 0302 clinical medicine, Postoperative Complications, SDG 3 - Good Health and Well-being, Risk Factors, Internal medicine, medicine, Humans, Retrospective Studies, Original Investigation, Models, Statistical, Performance status, Receiver operating characteristic, business.industry, Mortality rate, Esophageal cancer, Middle Aged, medicine.disease, Prognosis, Esophagectomy, 030220 oncology & carcinogenesis, Cohort, Surgery, Female, business, Body mass index
Abstract

Importance: Ninety-day mortality rates after esophagectomy are an indicator of the quality of surgical oncologic management. Accurate risk prediction based on large data sets may aid patients and surgeons in making informed decisions. Objective: To develop and validate a risk prediction model of death within 90 days after esophagectomy for cancer using the International Esodata Study Group (IESG) database, the largest existing prospective, multicenter cohort reporting standardized postoperative outcomes. Design, Setting, and Participants: In this diagnostic/prognostic study, we performed a retrospective analysis of patients from 39 institutions in 19 countries between January 1, 2015, and December 31, 2019. Patients with esophageal cancer were randomly assigned to development and validation cohorts. A scoring system that predicted death within 90 days based on logistic regression ß coefficients was conducted. A final prognostic score was determined and categorized into homogeneous risk groups that predicted death within 90 days. Calibration and discrimination tests were assessed between cohorts. Exposures: Esophageal resection for cancer of the esophagus and gastroesophageal junction. Main Outcomes and Measures: All-cause postoperative 90-day mortality. Results: A total of 8403 patients (mean [SD] age, 63.6 [9.0] years; 6641 [79.0%] male) were included. The 30-day mortality rate was 2.0% (n = 164), and the 90-day mortality rate was 4.2% (n = 353). Development (n = 4172) and validation (n = 4231) cohorts were randomly assigned. The multiple logistic regression model identified 10 weighted point variables factored into the prognostic score: age, sex, body mass index, performance status, myocardial infarction, connective tissue disease, peripheral vascular disease, liver disease, neoadjuvant treatment, and hospital volume. The prognostic scores were categorized into 5 risk groups: very low risk (score, =1; 90-day mortality, 1.8%), low risk (score, 0; 90-day mortality, 3.0%), medium risk (score, -1 to -2; 90-day mortality, 5.8%), high risk (score, -3 to -4: 90-day mortality, 8.9%), and very high risk (score, =-5; 90-day mortality, 18.2%). The model was supported by nonsignificance in the Hosmer-Lemeshow test. The discrimination (area under the receiver operating characteristic curve) was 0.68 (95% CI, 0.64-0.72) in the development cohort and 0.64 (95% CI, 0.60-0.69) in the validation cohort. Conclusions and Relevance: In this study, on the basis of preoperative variables, the IESG risk prediction model allowed stratification of an individual patient's risk of death within 90 days after esophagectomy. These data suggest that this model can help in the decision-making process when esophageal cancer surgery is being considered and in informed consent.

Published
2021
Full Text
View/download PDF

17. Pain and Opioid Consumption After Laparoscopic Versus Open Gastrectomy for Gastric Cancer:A Secondary Analysis of a Multicenter Randomized Clinical Trial (LOGICA-Trial)

Author

van der Veen, Arjen, Ramaekers, Mark, Marsman, Marije, Brenkman, Hylke J.F., Seesing, Maarten F.J., Luyer, Misha D.P., Nieuwenhuijzen, Grard A.P., Stoot, Jan H.M.B., Tegels, Juul J.W., Wijnhoven, Bas P.L., de Steur, Wobbe O., Kouwenhoven, Ewout A., Wassenaar, Eelco B., Draaisma, Werner A., Gisbertz, Suzanne S., van der Peet, Donald L., May, Anne M., Ruurda, Jelle P., van Hillegersberg, Richard, Haverkamp, Leonie, Ponten, Jeroen E.H., Heesakkers, Fanny F.B.M., Hulsewe, Karel W.E., Tweed, Thais T.T., Lagarde, Sjoerd M., van Lanschot, Jan J.B., Hartgrink, Henk H., van Det, Marc J., van Duijvendijk, Peter, van der Zaag, Edwin S., Broeders, Ivo A.M.J., van Berge Henegouwen, Mark I., Daams, Freek, van der Veen, Arjen, Ramaekers, Mark, Marsman, Marije, Brenkman, Hylke J.F., Seesing, Maarten F.J., Luyer, Misha D.P., Nieuwenhuijzen, Grard A.P., Stoot, Jan H.M.B., Tegels, Juul J.W., Wijnhoven, Bas P.L., de Steur, Wobbe O., Kouwenhoven, Ewout A., Wassenaar, Eelco B., Draaisma, Werner A., Gisbertz, Suzanne S., van der Peet, Donald L., May, Anne M., Ruurda, Jelle P., van Hillegersberg, Richard, Haverkamp, Leonie, Ponten, Jeroen E.H., Heesakkers, Fanny F.B.M., Hulsewe, Karel W.E., Tweed, Thais T.T., Lagarde, Sjoerd M., van Lanschot, Jan J.B., Hartgrink, Henk H., van Det, Marc J., van Duijvendijk, Peter, van der Zaag, Edwin S., Broeders, Ivo A.M.J., van Berge Henegouwen, Mark I., and Daams, Freek

Abstract

Background:Laparoscopic gastrectomy could reduce pain and opioid consumption, compared to open gastrectomy. However, it is difficult to judge the clinical relevance of this reduction, since these outcomes are reported in few randomized trials and in limited detail. Methods: This secondary analysis of a multicenter randomized trial compared laparoscopic versus open gastrectomy for resectable gastric adenocarcinoma (cT1-4aN0-3bM0). Postoperative pain was analyzed by opioid consumption in oral morphine equivalents (OME, mg/day) at postoperative day (POD) 1–5, WHO analgesic steps, and Numeric Rating Scales (NRS, 0–10) at POD 1–10 and discharge. Regression and mixed model analyses were performed, with and without correction for epidural analgesia. Results: Between 2015 and 2018, 115 patients in the laparoscopic group and 110 in the open group underwent surgery. Some 16 patients (14%) in the laparoscopic group and 73 patients (66%) in the open group received epidural analgesia. At POD 1–3, mean opioid consumption was 131, 118, and 53 mg OME lower in the laparoscopic group, compared to the open group, respectively (all p < 0.001). After correcting for epidural analgesia, these differences remained significant at POD 1–2 (47 mg OME, p = 0.002 and 69 mg OME, p < 0.001, respectively). At discharge, 27% of patients in the laparoscopic group and 43% patients in the open group used oral opioids (p = 0.006). Mean highest daily pain scores were between 2 and 4 at all PODs, < 2 at discharge, and did not relevantly differ between treatment arms. Conclusion: In this multicenter randomized trial, postoperative pain was comparable between laparoscopic and open gastrectomy. After laparoscopic gastrectomy, this was generally achieved without epidural analgesia and with fewer opioids. Trial Registration: NCT02248519.

Published
2023

18. Esophageal cancer patients’ need for information and support in making a treatment decision between standard surgery and active surveillance

Author

Hermus, Merel, van der Wilk, Berend J., Chang, Rebecca, Dekker, Jan Willem T., Coene, Peter Paul L.O., Nieuwenhuijzen, Grard A.P., Rosman, Camiel, Heisterkamp, Joos, Hartgrink, Henk H., Timmermans, Liesbeth, Wijnhoven, Bas P.L., van der Zijden, Charlène J., van Lanschot, Jan J.B., Busschbach, Jan, Lagarde, Sjoerd M., Kranenburg, Leonieke W., Hermus, Merel, van der Wilk, Berend J., Chang, Rebecca, Dekker, Jan Willem T., Coene, Peter Paul L.O., Nieuwenhuijzen, Grard A.P., Rosman, Camiel, Heisterkamp, Joos, Hartgrink, Henk H., Timmermans, Liesbeth, Wijnhoven, Bas P.L., van der Zijden, Charlène J., van Lanschot, Jan J.B., Busschbach, Jan, Lagarde, Sjoerd M., and Kranenburg, Leonieke W.

Abstract

Background: This study explores patients’ need for information and support in deciding on esophageal cancer treatment, when experimental active surveillance and standard surgery are both feasible. Methods: This psychological companion study was conducted alongside the Dutch SANO-trial (Surgery As Needed for Oesophageal cancer). In-depth interviews and questionnaires were used to collect data from patients who declined participation in the trial because they had a strong preference for either active surveillance (n = 20) or standard surgery (n = 20). Data were analyzed using both qualitative and quantitative techniques. Results: Patients prefer to receive information directly from their doctors and predominantly rely on this information to make a treatment decision. Other information resources are largely used to confirm their treatment decision. Patients highly value support from their loved ones and appreciate emphatic doctors to actively involve them in the decision-making process. Overall, patients’ needs for information and support during decision-making were met.Conclusions: The importance of shared decision-making and the role doctors have in this process is underlined. The role of doctors is essential at the initial phase of decision-making: Once patients seem to have formed their treatment preference for either active surveillance or surgery, the influence of external resources (including doctors) may be limited.

Published
2023

19. Surgeon's steering behaviour towards patients to participate in a cluster randomised trial on active surveillance for oesophageal cancer:A qualitative study

Author

de Veer, Mathijs R., Hermus, Merel, van der Zijden, Charlène J., van der Wilk, Berend J., Wijnhoven, Bas P.L., Stiggelbout, Anne M., Dekker, Jan Willem T., Coene, Peter Paul L.O., Busschbach, Jan J., van Lanschot, Jan J.B., Lagarde, Sjoerd M., Kranenburg, Leonieke W., de Veer, Mathijs R., Hermus, Merel, van der Zijden, Charlène J., van der Wilk, Berend J., Wijnhoven, Bas P.L., Stiggelbout, Anne M., Dekker, Jan Willem T., Coene, Peter Paul L.O., Busschbach, Jan J., van Lanschot, Jan J.B., Lagarde, Sjoerd M., and Kranenburg, Leonieke W.

Abstract

Introduction: Few studies have been conducted into how physicians use steering behaviour that may persuade patients to choose for a particular treatment, let alone to participate in a randomised trial. The aim of this study is to assess if and how surgeons use steering behaviour in their information provision to patients in their choice to participate in a stepped-wedge cluster randomised trial investigating an organ sparing treatment in (curable) oesophageal cancer (SANO trial). Materials and methods: A qualitative study was performed. Thematic content analysis was applied to audiotaped and transcribed consultations of twenty patients with eight different oncological surgeons in three Dutch hospitals. Patients could choose to participate in a clinical trial in which an experimental treatment of ‘active surveillance’ (AS) was offered. Patients who did not want to participate underwent standard treatment: neoadjuvant chemoradiotherapy followed by oesophagectomy. Results: Surgeons used various techniques to steer patients towards one of the two options, mostly towards AS. The presentation of pros and cons of treatment options was imbalanced: positive framing of AS was used to steer patients towards the choice for AS, and negative framing of AS to make the choice for surgery more attractive. Further, steering language, i.e. suggestive language, was used, and surgeons seemed to use the timing of the introduction of the different treatment options, to put more focus on one of the treatment options. Conclusion: Awareness of steering behaviour can help to guide physicians in more objectively informing patients on participation in future clinical trials.

Published
2023

20. The need for information and support in decision-making for patients with esophageal cancer who prefer standard surgery or active surveillance

Author

Hermus, Merel, primary, van der Wilk, Berend, additional, Chang, Rebecca, additional, Dekker, Jan Willem, additional, Coene, Peter-Paul, additional, Nieuwenhuijzen, Grard, additional, Rosman, Camiel, additional, Heisterkamp, Joos, additional, Hartgrink, Henk, additional, Wijnhoven, Bas, additional, van der Zijden, Charlène, additional, van Lanschot, Jan, additional, van Busschbach, Jan, additional, Lagarde, Sjoerd, additional, and Kranenburg, Leonieke, additional

Published
2023
Full Text
View/download PDF

24. Using the Comprehensive Complication Index to Assess the Impact of Neoadjuvant Chemoradiotherapy on Complication Severity After Esophagectomy for Cancer

Author

Nederlof, Nina, Slaman, Annelijn E., van Hagen, Pieter, van der Gaast, Ate, Slankamenac, Ksenija, Gisbertz, Suzanne S., van Lanschot, Jan J. B., Wijnhoven, Bas P. L., van Berge Henegouwen, Mark I., Bonenkamp, J. J., Busch, O. R. C., Cuesta, M. A., Nieuwenhuijzen, G. A. P., Plukker, J. T. M., Spillenaar Bilgen, E. J., Tilanus, H. W., and CROSS-Study Group

Published
2016
Full Text
View/download PDF

25. 508. OUTCOME OF NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN EAST ASIA VERSUS WESTERN EUROPE

Author

Eyck, Ben, primary, Gao, Xing, additional, Yang, Yang, additional, van der Wilk, Berend, additional, Wong, Ian, additional, Wijnhoven, Bas, additional, Liu, J, additional, Lagarde, Sjoerd, additional, Lam, KO, additional, Hulshof, M, additional, Li, Zhi Gang, additional, Law, Simon, additional, Chao, Yin Kai, additional, and van Lanschot, Jan, additional

Published
2022
Full Text
View/download PDF

26. 266. EXTENSION OF FDG-PET-BASED RADIOMIC MODELS ON IDENTIFICATION OF PATIENTS WITH RESIDUAL ESOPHAGEAL CANCER AFTER NEOADJUVANT CHEMORADIOTHERAPY

Author

Valkema, Maria Joanna, primary, Beukinga, Roelof, additional, Chatterjee, Avishek, additional, Woodruff, Henry, additional, van Klaveren, David, additional, Noordzij, Walter, additional, Valkema, Roelf, additional, Bennink, Roel, additional, Roef, Mark, additional, Schreurs, Wendy, additional, Doukas, Michail, additional, Lagarde, Sjoerd, additional, Wijnhoven, Bas, additional, Lambin, Philippe, additional, Plukker, John, additional, and van Lanschot, Jan, additional

Published
2022
Full Text
View/download PDF

31. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer – Differential treatment strategies for subtypes of early gastroesophageal cancer

Author

Lutz, Manfred P., Zalcberg, John R., Ducreux, Michel, Ajani, Jaffer A., Allum, William, Aust, Daniela, Bang, Yung-Jue, Cascinu, Stefano, Hölscher, Arnulf, Jankowski, Janusz, Jansen, Edwin P.M., Kisslich, Ralf, Lordick, Florian, Mariette, Christophe, Moehler, Markus, Oyama, Tsuneo, Roth, Arnaud, Rueschoff, Josef, Ruhstaller, Thomas, Seruca, Raquel, Stahl, Michael, Sterzing, Florian, van Cutsem, Eric, van der Gaast, Ate, van Lanschot, Jan, Ychou, Marc, and Otto, Florian

Published
2012
Full Text
View/download PDF

32. Lasting Symptoms After Esophageal Resection (LASER):European Multicenter Cross-sectional Study

Author

Markar, Sheraz R., Zaninotto, Giovanni, Castoro, Carlo, Johar, Asif, Lagergren, Pernilla, Elliott, Jessie A., Gisbertz, Suzanne S., Mariette, Christophe, Alfieri, Rita, Huddy, Jeremy, Sounderajah, Viknesh, Pinto, Eleonora, Scarpa, Marco, Klevebro, Fredrik, Sunde, Berit, Murphy, Conor F., Greene, Christine, Ravi, Narayanasamy, Piessen, Guillaume, Brenkman, Hylke, Ruurda, Jelle P., Van Hillegersberg, Richard, Lagarde, Sjoerd, Wijnhoven, Bas, Pera, Manuel, Roig, José, Castro, Sandra, Matthijsen, Robert, Findlay, John, Antonowicz, Stefan, Maynard, Nick, Mccormack, Orla, Ariyarathenam, Arun, Sanders, Grant, Cheong, Edward, Jaunoo, Shameen, Allum, William, Van Lanschot, Jan, Nilsson, Magnus, Reynolds, John V., Henegouwen, Mark I.van Berge, Hanna, George B., Markar, Sheraz R., Zaninotto, Giovanni, Castoro, Carlo, Johar, Asif, Lagergren, Pernilla, Elliott, Jessie A., Gisbertz, Suzanne S., Mariette, Christophe, Alfieri, Rita, Huddy, Jeremy, Sounderajah, Viknesh, Pinto, Eleonora, Scarpa, Marco, Klevebro, Fredrik, Sunde, Berit, Murphy, Conor F., Greene, Christine, Ravi, Narayanasamy, Piessen, Guillaume, Brenkman, Hylke, Ruurda, Jelle P., Van Hillegersberg, Richard, Lagarde, Sjoerd, Wijnhoven, Bas, Pera, Manuel, Roig, José, Castro, Sandra, Matthijsen, Robert, Findlay, John, Antonowicz, Stefan, Maynard, Nick, Mccormack, Orla, Ariyarathenam, Arun, Sanders, Grant, Cheong, Edward, Jaunoo, Shameen, Allum, William, Van Lanschot, Jan, Nilsson, Magnus, Reynolds, John V., Henegouwen, Mark I.van Berge, and Hanna, George B.

Abstract

Objective:To identify the most prevalent symptoms and those with greatest impact upon health-related quality of life (HRQOL) among esophageal cancer survivors.Background:Long-term symptom burden after esophagectomy, and associations with HRQOL, are poorly understood.Patients and Methods:Between 2010 and 2016, patients from 20 European Centers who underwent esophageal cancer surgery, and were disease-free at least 1 year postoperatively were asked to complete LASER, EORTC-QLQ-C30, and QLQ-OG25 questionnaires. Specific symptom questionnaire items that were associated with poor HRQOL as identified by EORTC QLQ-C30 and QLQ-OG25 were identified by multivariable regression analysis and combined to form a tool.Results:A total of 876 of 1081 invited patients responded to the questionnaire, giving a response rate of 81%. Of these, 66.9% stated in the last 6 months they had symptoms associated with their esophagectomy. Ongoing weight loss was reported by 10.4% of patients, and only 13.8% returned to work with the same activities.Three LASER symptoms were correlated with poor HRQOL on multivariable analysis; pain on scars on chest (odds ratio (OR) 1.27; 95% CI 0.97-1.65), low mood (OR 1.42; 95% CI 1.15-1.77) and reduced energy or activity tolerance (OR 1.37; 95% CI 1.18-1.59). The areas under the curves for the development and validation datasets were 0.81 ± 0.02 and 0.82 ± 0.09 respectively.Conclusion:Two-thirds of patients experience significant symptoms more than 1 year after surgery. The 3 key symptoms associated with poor HRQOL identified in this study should be further validated, and could be used in clinical practice to identify patients who require increased support.

Published
2022

33. Lasting Symptoms After Esophageal Resection (LASER): European Multicenter Cross-sectional Study

Author

MS CGO, Cancer, Markar, Sheraz R, Zaninotto, Giovanni, Castoro, Carlo, Johar, Asif, Lagergren, Pernilla, Elliott, Jessie A, Gisbertz, Suzanne S, Mariette, Christophe, Alfieri, Rita, Huddy, Jeremy, Sounderajah, Viknesh, Pinto, Eleonora, Scarpa, Marco, Klevebro, Fredrik, Sunde, Berit, Murphy, Conor F, Greene, Christine, Ravi, Narayanasamy, Piessen, Guillaume, Brenkman, Hylke, Ruurda, Jelle P, Van Hillegersberg, Richard, Lagarde, Sjoerd, Wijnhoven, Bas, Pera, Manuel, Roig, José, Castro, Sandra, Matthijsen, Robert, Findlay, John, Antonowicz, Stefan, Maynard, Nick, McCormack, Orla, Ariyarathenam, Arun, Sanders, Grant, Cheong, Edward, Jaunoo, Shameen, Allum, William, Van Lanschot, Jan, Nilsson, Magnus, Reynolds, John V, Henegouwen, Mark I van Berge, Hanna, George B, MS CGO, Cancer, Markar, Sheraz R, Zaninotto, Giovanni, Castoro, Carlo, Johar, Asif, Lagergren, Pernilla, Elliott, Jessie A, Gisbertz, Suzanne S, Mariette, Christophe, Alfieri, Rita, Huddy, Jeremy, Sounderajah, Viknesh, Pinto, Eleonora, Scarpa, Marco, Klevebro, Fredrik, Sunde, Berit, Murphy, Conor F, Greene, Christine, Ravi, Narayanasamy, Piessen, Guillaume, Brenkman, Hylke, Ruurda, Jelle P, Van Hillegersberg, Richard, Lagarde, Sjoerd, Wijnhoven, Bas, Pera, Manuel, Roig, José, Castro, Sandra, Matthijsen, Robert, Findlay, John, Antonowicz, Stefan, Maynard, Nick, McCormack, Orla, Ariyarathenam, Arun, Sanders, Grant, Cheong, Edward, Jaunoo, Shameen, Allum, William, Van Lanschot, Jan, Nilsson, Magnus, Reynolds, John V, Henegouwen, Mark I van Berge, and Hanna, George B

Published
2022

34. Outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal squamous cell carcinoma in East Asia versus Western Europe

Author

Eyck, Ben, primary, Gao, Xing, additional, Yang, Yang, additional, van der Wilk, Berend, additional, Wong, Ian, additional, Wijnhoven, Bas, additional, Liu, Jun, additional, Lagarde, Sjoerd, additional, Lam, Ka On, additional, Hulshof, Maarten, additional, Li, Zhigang, additional, Law, Simon, additional, Chao, Yin Kai, additional, and van Lanschot, Jan, additional

Published
2022
Full Text
View/download PDF

35. Patient preferences for active surveillance versus standard surgery after neoadjuvant chemoradiotherapy in esophageal cancer treatment

Author

Hermus, Merel, primary, van der Wilk, Berend, additional, Collee, Gerlise, additional, Chang, Rebecca, additional, Noordman, Bo, additional, Dekker, Jan Willem, additional, van Esser, Stijn, additional, Nieuwenhuijzen, Grard, additional, Luyer, Misha, additional, Rosman, Camiel, additional, Klarenbeek, Bastiaan, additional, Coene, Peter-Paul, additional, van der Harst, Erwin, additional, Wijnhoven, Bas, additional, van Busschbach, Jan, additional, van Lanschot, Jan, additional, Lagarde, Sjoerd, additional, and Kranenburg, Leonieke, additional

Published
2022
Full Text
View/download PDF

39. Intrathoracic vs Cervical Anastomosis after Totally or Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer: A Randomized Clinical Trial: A Randomized Clinical Trial

Author

van Workum, Frans, Verstegen, Moniek H. P., Klarenbeek, Bastiaan R., Bouwense, Stefan A. W., van Berge Henegouwen, Mark I., Daams, Freek, Gisbertz, Suzanne S., Hannink, Gerjon, Haveman, Jan Willem, Heisterkamp, Joos, Jansen, Walther, Kouwenhoven, Ewout A., van Lanschot, Jan J. B., Nieuwenhuijzen, Grard A. P., van der Peet, Donald L., Polat, Fatih, Ubels, Sander, Wijnhoven, Bas P. L., Rovers, Maroeska M., Rosman, Camiel, Surgery, CCA - Cancer Treatment and quality of life, Amsterdam Gastroenterology Endocrinology Metabolism, and VU University medical center

Abstract

Background: Transthoracic minimally invasive esophagectomy (MIE) is increasingly performed as part of curative multimodality treatment. There appears to be no robust evidence on the preferred location of the anastomosis after transthoracic MIE. Objective: To compare an intrathoracic with a cervical anastomosis in a randomized clinical trial. Design, Setting, and Participants: This open, multicenter randomized clinical superiority trial was performed at 9 Dutch high-volume hospitals. Patients with midesophageal to distal esophageal or gastroesophageal junction cancer planned for curative resection were included. Data collection occurred from April 2016 through February 2020. Intervention: Patients were randomly assigned (1:1) to transthoracic MIE with intrathoracic or cervical anastomosis. Main Outcomes and Measures: The primary end point was anastomotic leakage requiring endoscopic, radiologic, or surgical intervention. Secondary outcomes were overall anastomotic leak rate, other postoperative complications, length of stay, mortality, and quality of life. Results: Two hundred sixty-two patients were randomized, and 245 were eligible for analysis. Anastomotic leakage necessitating reintervention occurred in 15 of 122 patients with intrathoracic anastomosis (12.3%) and in 39 of 123 patients with cervical anastomosis (31.7%; risk difference, -19.4% [95% CI, -29.5% to -9.3%]). Overall anastomotic leak rate was 12.3% in the intrathoracic anastomosis group and 34.1% in the cervical anastomosis group (risk difference, -21.9% [95% CI, -32.1% to -11.6%]). Intensive care unit length of stay, mortality rates, and overall quality of life were comparable between groups, but intrathoracic anastomosis was associated with fewer severe complications (risk difference, -11.3% [-20.4% to -2.2%]), lower incidence of recurrent laryngeal nerve palsy (risk difference, -7.3% [95% CI, -12.1% to -2.5%]), and better quality of life in 3 subdomains (mean differences: dysphagia, -12.2 [95% CI, -19.6 to -4.7]; problems of choking when swallowing, -10.3 [95% CI, -16.4 to 4.2]; trouble with talking, -15.3 [95% CI, -22.9 to -7.7]). Conclusions and Relevance: In this randomized clinical trial, intrathoracic anastomosis resulted in better outcome for patients treated with transthoracic MIE for midesophageal to distal esophageal or gastroesophageal junction cancer. Trial Registration: Trialregister.nl Identifier: NL4183 (NTR4333).

Published
2021
Full Text
View/download PDF

46. Original Study:Development of a Reliable Surgical Quality Assurance System for 2-stage Esophagectomy in Randomized Controlled Trials

Author

Harris, Alexander, Butterworth, James, Boshier, Piers R, MacKenzie, Hugh, Tokunaga, Masanori, Sunagawa, Hideki, Mavroveli, Stella, Ni, Melody, Mikhail, Sameh, Yeh, Chi-Chuan, Blencowe, Natalie S, Avery, Kerry N L, Hardwick, Richard, Hoelscher, Arnulf, Pera, Manuel, Zaninotto, Giovanni, Law, Simon, Low, Donald E, van Lanschot, Jan J B, Berrisford, Richard ChM, Blazeby, Jane M, Hanna, George, and Barham, Christopher Paul

Subjects
surgical quality assurance, esophagectomy, esophageal cancer
Abstract

Objective: The aim was to develop a reliable surgical quality assurance system for 2-stage esophagectomy. This development was conducted during the pilot phase of the multicenter ROMIO trial, collaborating with international experts.Summary of Background Data: There is evidence that the quality of surgical performance in randomized controlled trials influences clinical outcomes, quality of lymphadenectomy and loco-regional recurrence.Methods: Standardization of 2-stage esophagectomy was based on structured observations, semi-structured interviews, hierarchical task analysis, and a Delphi consensus process. This standardization provided the structure for the operation manual and video and photographic assessment tools. Reliability was examined using generalizability theory.Results: Hierarchical task analysis for 2-stage esophagectomy comprised fifty-four steps. Consensus (75%) agreement was reached on thirty-nine steps, whereas fifteen steps had a majority decision. An operation manual and record were created. A thirty five-item video assessment tool was developed that assessed the process (safety and efficiency) and quality of the end product (anatomy exposed and lymphadenectomy performed) of the operation. The quality of the end product section was used as a twenty seven-item photographic assessment tool. Thirty-one videos and fifty-three photographic series were submitted from the ROMIO pilot phase for assessment. The overall G-coefficient for the video assessment tool was 0.744, and for the photographic assessment tool was 0.700.Conclusions: A reliable surgical quality assurance system for 2-stage esophagectomy has been developed for surgical oncology randomized controlled trials.Ethical approval: 11/NW/0895 and confirmed locally as appropriate, 12/SW/0161, 16/SW/0098.Trial registration number: ISRCTN59036820, ISRCTN10386621.

Published
2020

47. 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer: A Multicenter Prospective Dutch Cohort Study (PLASTIC)

Author

Verpleegafd Vaatchirurgie D4 Oost, MS CGO, Cancer, MS Radiologie, MS Medische Oncologie, HEE, Child Health, JC onderzoeksprogramma Methodologie, Gertsen, Emma C., Brenkman, Hylke J.F., Van Hillegersberg, Richard, Van Sandick, Johanna W., Van Berge Henegouwen, Mark I., Gisbertz, Suzanne S., Luyer, Misha D.P., Nieuwenhuijzen, Grard A.P., Van Lanschot, Jan J.B., Lagarde, Sjoerd M., Wijnhoven, Bas P.L., De Steur, Wobbe O., Hartgrink, Henk H., Stoot, Jan H.M.B., Hulsewe, Karel W.E., Spillenaar Bilgen, Ernst J., Van Det, Marc J., Kouwenhoven, Ewout A., Van Der Peet, Donald L., Daams, Freek, Van Grieken, Nicole C.T., Heisterkamp, Joos, Van Etten, Boudewijn, Van Den Berg, Jan Willem, Pierie, Jean Pierre, Eker, Hasan H., Thijssen, Annemieke Y., Belt, Eric J.T., Van Duijvendijk, Peter, Wassenaar, Eelco, Van Laarhoven, Hanneke W.M., Wevers, Kevin P., Hol, Lieke, Wessels, Frank J., Haj Mohammad, Nadia, Van Der Meulen, Miriam P., Frederix, Geert W.J., Vegt, Erik, Siersema, Peter D., Ruurda, Jelle P., Verpleegafd Vaatchirurgie D4 Oost, MS CGO, Cancer, MS Radiologie, MS Medische Oncologie, HEE, Child Health, JC onderzoeksprogramma Methodologie, Gertsen, Emma C., Brenkman, Hylke J.F., Van Hillegersberg, Richard, Van Sandick, Johanna W., Van Berge Henegouwen, Mark I., Gisbertz, Suzanne S., Luyer, Misha D.P., Nieuwenhuijzen, Grard A.P., Van Lanschot, Jan J.B., Lagarde, Sjoerd M., Wijnhoven, Bas P.L., De Steur, Wobbe O., Hartgrink, Henk H., Stoot, Jan H.M.B., Hulsewe, Karel W.E., Spillenaar Bilgen, Ernst J., Van Det, Marc J., Kouwenhoven, Ewout A., Van Der Peet, Donald L., Daams, Freek, Van Grieken, Nicole C.T., Heisterkamp, Joos, Van Etten, Boudewijn, Van Den Berg, Jan Willem, Pierie, Jean Pierre, Eker, Hasan H., Thijssen, Annemieke Y., Belt, Eric J.T., Van Duijvendijk, Peter, Wassenaar, Eelco, Van Laarhoven, Hanneke W.M., Wevers, Kevin P., Hol, Lieke, Wessels, Frank J., Haj Mohammad, Nadia, Van Der Meulen, Miriam P., Frederix, Geert W.J., Vegt, Erik, Siersema, Peter D., and Ruurda, Jelle P.

Published
2021

50. 10-year outcome of a randomized trial comparing neoadjuvant chemoradiotherapy and surgery with surgery alone for esophageal cancer (CROSS trial)

Author

Eyck, Ben, primary, van Lanschot, Jan, additional, Hulshof, Maarten, additional, van Berge Henegouwen, Mark, additional, van Laarhoven, Hanneke, additional, Nieuwenhuijzen, Grard, additional, Hospers, Geke, additional, Johannes, Bonenkamp, additional, Cuesta, Miguel, additional, Creemers, Geert Jan, additional, Punt, Cornelis, additional, Plukker, John, additional, Verheul, Henk, additional, Bilgen, Ernst Spillenaar, additional, van der Sangen, Maurice, additional, Kate, Fiebo Ten, additional, van Rij, Caroline, additional, Steyerberg, Ewout, additional, and van der Gaast, Ate, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results